Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263081 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
NCT00263081 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 44 participants.
The verdict
NCT00263081, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.
Interventions
- DRUG Lapaquistat acetate and current lipid-lowering treatment
- DRUG Current lipid-lowering treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00263081
The ClinicalTrials.gov registry entry for NCT00263081 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapaquistat acetate and current lipid-lowering treatment is the first listed.
NCT00263081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00263081 about?
NCT00263081 is a clinical study titled "Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia". The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), to lower cholesterol in subjects with homozygous familial hypercholesterolemia undergoing lipid-lowering treatment.
What is the current status of trial NCT00263081?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2005-11. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00263081?
The interventions under investigation include: Lapaquistat acetate and current lipid-lowering treatment (DRUG), Current lipid-lowering treatment (DRUG).
Who is sponsoring clinical trial NCT00263081?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.